Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration

References

• Wong W. Managed care opportunities and approaches to select treatment for sight preservation. Am J Manag Care. 2020;26:S112–S117. doi:10.37765/ajmc.2020.43436
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Krebs I, Glittenberg C, Ansari-Shahrezaei S, et al. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol. 2013;97(11):1443–1446. doi:10.1136/bjophthalmol-2013-303513
   PubMed Web of Science ®Google Scholar
• Nagai N, Suzuki M, Uchida A, et al. Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment. Sci Rep. 2016;6(6):29619. doi:10.1038/srep29619
   PubMedGoogle Scholar
• Maguire MG, Martin DF, Ying GS, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–1761. doi:10.1016/j.ophtha.2016.03.045
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226. doi:10.1136/bjophthalmol-2014-305327
   PubMed Web of Science ®Google Scholar
• Ohji M, Takahashi K, Okada AA, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020;37(3):1173–1187. doi:10.1007/s12325-020-01236-x
   PubMed Web of Science ®Google Scholar
• Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89–99. doi:10.1016/j.ophtha.2020.06.028
   PubMed Web of Science ®Google Scholar
• Mones J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128(7):1050–1059. doi:10.1016/j.ophtha.2020.11.011
   PubMed Web of Science ®Google Scholar
• Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific crossmab optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265–1288. doi:10.15252/emmm.201505889
   PubMed Web of Science ®Google Scholar
• Sharma N, Kumar N, Kuppermann BD, et al. Faricimab: expanding horizon beyond VEGF. Eye. 2020;34(5):802–804. doi:10.1038/s41433-019-0670-1
   PubMed Web of Science ®Google Scholar
• Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–740. doi:10.1016/S0140-6736(22)00010-1
   PubMed Web of Science ®Google Scholar
• Mori R, Honda S, Gomi F, et al. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Jpn J Ophthalmol. 2023;67(3):301–310. doi:10.1007/s10384-023-00985-w
   PubMed Web of Science ®Google Scholar
• Hata M, Tsujikawa A, Miyake M, et al. Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(2):221–227. doi:10.1007/s00417-014-2688-1
   PubMed Web of Science ®Google Scholar
• Miyake M, Ooto S, Yamashiro K, et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep. 2015;5(1):16204. doi:10.1038/srep16204
   PubMed Web of Science ®Google Scholar
• Kuo HK, Kuo MT, Tiong IS, et al. Visual acuity as measured with landolt c chart and early treatment of diabetic retinopathy study chart. Graefes Arch Clin Exp Ophthalmol. 2011;249(4):601–605. doi:10.1007/s00417-010-1461-3
   PubMed Web of Science ®Google Scholar
• Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146(4):496–500. doi:10.1016/j.ajo.2008.05.032
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Hata M, Oishi A, et al. Association of vascular versus avascular subretinal hyperreflective material with aflibercept response in age-related macular degeneration. Am J Ophthalmol. 2017;181:61–70. doi:10.1016/j.ajo.2017.06.015
   PubMed Web of Science ®Google Scholar
• Tagawa M, Ooto S, Yamashiro K, et al. Characteristics of pachychoroid neovasculopathy. Sci Rep. 2020;10(1):16248. doi:10.1038/s41598-020-73303-w
   PubMed Web of Science ®Google Scholar
• Hata M, Yamashiro K, Ooto S, et al. Intraocular vascular endothelial growth factor levels in pachychoroid neovasculopathy and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58(1):292–298. doi:10.1167/iovs.16-20967
   PubMed Web of Science ®Google Scholar
• Dansingani KK, Balaratnasingam C, Naysan J, et al. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina. 2016;36(3):499–516. doi:10.1097/IAE.0000000000000742
   PubMed Web of Science ®Google Scholar
• Pang CE, Shah VP, Sarraf D, et al. Ultra-widefield imaging with autofluorescence and indocyanine green angiography in central serous chorioretinopathy. Am J Ophthalmol. 2014;158(2):362–371.e2. doi:10.1016/j.ajo.2014.04.021
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group. The age-related eye disease study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the age-related eye disease study report number 6. Am J Ophthalmol. 2001;132(5):668–681. doi:10.1016/S0002-9394(01)01218-1
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Hoshino J, Nakamura K, et al. Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023;261(10):2945–2952. doi:10.1007/s00417-023-06116-y
   PubMed Web of Science ®Google Scholar
• Mukai R, Kataoka K, Tanaka K, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13(1):8747. doi:10.1038/s41598-023-35759-4
   PubMed Web of Science ®Google Scholar
• Maruko M, Ogasawara M, Yamamoto A, et al. Two-year outcomes of treat-and-extend intravitreal aflibercept for exudative age-related macular degeneration: a prospective study. Ophthalmol Retina. 2020;4(8):767–776. doi:10.1016/j.oret.2020.03.010
   PubMedGoogle Scholar
• Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35(1):1–9. doi:10.1097/IAE.0000000000000331
   PubMed Web of Science ®Google Scholar
• Chang YC, Cheng CK. Difference between pachychoroid and nonpachychoroid polypoidal choroidal vasculopathy and their response to anti-vascular endothelial growth factor therapy. Retina. 2020;40(7):1403–1411. doi:10.1097/IAE.0000000000002583
   PubMed Web of Science ®Google Scholar
• Inoda S, Takahashi H, Inoue Y, et al. Cytokine profiles of macular neovascularization in the elderly based on a classification from a pachychoroid/drusen perspective. Graefes Arch Clin Exp Ophthalmol. 2022;260(3):747–758. doi:10.1007/s00417-021-05445-0
   PubMed Web of Science ®Google Scholar
• Oishi A, Tsujikawa A, Yamashiro K, et al. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol. 2015;159(5):853–860.e1. doi:10.1016/j.ajo.2015.01.018
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1–24. doi:10.1016/j.preteyeres.2015.07.007
   PubMed Web of Science ®Google Scholar